Mayer et al. [32] showed that p110α-specific inhibitor Alpelisib combined with letrozole was safe and effective in the treatment of patients with resistant ER + metastatic breast cancer, while Alpelisib displayed a more obvious effect on breast cancer patients carrying PIK3CA mutations. The gene discussed is PIK3CA; the disease is breast carcinoma.